Global Pulse

分类： health

  • Parents and teachers in Congo urge delay of school resumption as Ebola outbreak rages on

    Parents and teachers in Congo urge delay of school resumption as Ebola outbreak rages on

    In the heart of the Democratic Republic of the Congo’s fastest-expanding Ebola outbreak on record, caregivers and educators are pressing regional and national authorities to postpone the nationwide school reopening scheduled for September 1, warning that unchecked community spread continues to put children at catastrophic risk.

    Centered in Congo’s eastern Ituri province, the ongoing outbreak has already reached staggering public health proportions: Congolese health authorities confirm 5,713 confirmed infections and 2,744 recorded deaths to date, with transmission outpacing all containment efforts. This epidemic, which official data traces back to February despite an official declaration in mid-May, has ballooned from three initial affected health zones to nearly 60 across the country, with the majority of new cases and deaths occurring in unmonitored community settings rather than clinical facilities. The World Health Organization has confirmed the outbreak remains fully out of control and is on track to surpass the 2014–2016 West Africa Ebola epidemic, the deadliest in recorded history that killed more than 11,000 people.

    Comprehensive public health data from the outbreak reveals a particularly alarming risk for young children: kids aged 4 and under face a 60% case-fatality rate, the highest mortality rate of any age group impacted by the virus. This stark statistic has fueled growing calls from local stakeholders to delay the scheduled return to classrooms, even as many families and educators acknowledge the urgent need to resume interrupted learning.

    “We want to get back to teaching, but not at the cost of our lives or the lives of our students,” said Fazila Rebecca, a primary school teacher based in Bunia, the capital of Ituri province, in an interview with the Associated Press. “As long as the virus is still circulating widely in our communities and sufficient protective measures are not in place, opening our school doors is a risk we simply cannot afford to take.”

    On Tuesday, the Ituri regional teachers union held an emergency assembly in Bunia, formally calling on public health authorities to conduct a full, transparent assessment of current transmission rates before finalizing any decision on school reopening. “We are not against resuming classes — we just believe that the health and safety of every teacher and every student has to come first,” explained Budju Lobo Isaac, a representative for the union. Ituri authorities had not issued a public response to the union’s request or growing public pressure as of Thursday.

    The current outbreak has been amplified by a perfect storm of systemic challenges: chronic regional insecurity from rebel violence, mass population displacement, a recent strike by frontline health workers, and constant cross-community population movement have all hampered containment efforts. Beyond logistical barriers, the strain of the outbreak is exacerbated by the fact that it is driven by the rare Bundibugyo Ebola virus, for which no widely approved vaccines or specific treatments currently exist. While clinical trials for experimental vaccines and therapeutics are already underway in the region, no fully vetted, large-scale intervention is available to stop transmission at this time. The Congolese government has noted that it is set to receive 70,000 doses of Ervebo, an Ebola vaccine that proved effective against previous outbreaks of other Ebola strains, though its effectiveness against Bundibugyo remains unconfirmed.

    Widespread outbreak control measures, including limits on public gatherings, social distancing requirements, and regional airport closures, have already upended daily life across six affected provinces, particularly in Ituri, which has already been devastated by years of rebel conflict. While the national government has rolled out limited public health interventions, including the installation of basic sanitation equipment at high-traffic locations, child health advocacy groups say far more work is needed to both scale up protective resources and build community trust around public health guidance.

    “Beyond practical logistical challenges, community buy-in remains the most critical piece of outbreak response,” noted Greg Ramm, country director for Save the Children in the Democratic Republic of the Congo. “Our immediate priority right now is to make sure every school, every teacher, and every family has the accurate public health information and personal protective resources they need to make the start of the school year as safe as possible for every child.”

    For many parents in Bunia, the uncertainty around school reopening has created an impossible dilemma: many are eager to get their children back to structured learning after months of disruption, but fear the risk of viral exposure. “As a parent, I want my children in school — I know how important their education is,” said Espérance Dz’venga, who was purchasing school supplies for her children at Bunia’s central market this week. “But like every other parent, what I want most is for them to come home healthy at the end of the day. We are terrified that they will be exposed at school, and then bring the virus home to our whole families.”

  • US drug agency approves breakthrough treatment for pancreatic cancer

    US drug agency approves breakthrough treatment for pancreatic cancer

    In a landmark step forward for cancer care, the U.S. Food and Drug Administration (FDA) has greenlit a new targeted treatment for pancreatic cancer, one of the most lethal forms of the disease globally, after clinical data demonstrated it nearly doubles the average overall survival time for patients.

    Developed by biotech firm Revolution Medicines, the treatment, generically named daraxonrasib and sold under the brand name Rasonque, is being hailed as a long-awaited breakthrough for a cancer that has defied effective treatment for decades. Results from a late-stage clinical trial involving 500 pancreatic cancer patients revealed that participants who took the daily oral pill achieved a median overall survival of 13.2 months, compared to just 6.6 months for patients treated with standard chemotherapy.

    Unlike traditional chemotherapy that attacks both cancerous and healthy cells, daraxonrasib works through targeted precision: it binds to and inactivates the mutated KRAS gene, a genetic driver that fuels uncontrolled tumor growth. This specific mutation is present in more than 90% of all pancreatic tumors, making the treatment widely applicable for the most common form of the disease.

    Pancreatic cancer remains one of the deadliest major cancers, with grim statistics underscoring the urgent need for new treatment options. The American Cancer Society reports roughly 67,000 new cases are diagnosed in the U.S. each year, and the cancer carries the highest mortality rate among all common malignancies. Most cases are detected at an advanced stage after the cancer has already spread, and more than half of patients die within three months of receiving a diagnosis.

    The path to approval was accelerated due to the urgent unmet medical need for effective pancreatic cancer treatments. In 2025, the FDA awarded daraxonrasib a “Breakthrough Therapy” designation, a special status that streamlines review for treatments targeting serious, life-threatening conditions. The agency ultimately issued its approval six months ahead of its original regulatory deadline, a decision driven by the treatment’s unmatched trial results.

    Angelo de Claro, director of the FDA’s Oncology Center of Excellence, emphasized the transformative potential of the new approval, noting the drug “showed unprecedented results in an area of high unmet need.” The FDA itself described the treatment as a “critical new option for patients facing an extraordinarily difficult and historically hard-to-treat cancer.”

    Data on side effects also show the new treatment is better tolerated than traditional chemotherapy. While common adverse reactions include rash, diarrhea, nausea, fatigue and vomiting, the rate of severe side effects was 44% for patients taking daraxonrasib, compared to 57.5% for those on chemotherapy. High-profile patient outcomes have also highlighted the drug’s promise: former U.S. Senator Ben Sasse, who announced a Stage 4 pancreatic cancer diagnosis in December, is currently enrolled in the clinical trial and has confirmed the treatment has reduced the size of his tumors.

    This approval marks a turning point in pancreatic cancer care, opening a new door of hope for thousands of patients facing a diagnosis that has long carried very poor prognoses.

  • German airport worker dies of malaria after ‘mosquito arrives on plane’

    German airport worker dies of malaria after ‘mosquito arrives on plane’

    A rare local malaria outbreak at Germany’s busiest travel hub, Frankfurt Airport, has claimed the life of one employee and left five others infected with the mosquito-borne disease, public health and airport authorities have confirmed.

    German public health officials trace the origin of the disease-carrying mosquitoes to incoming air travel, saying the insects likely hitched a ride on commercial aircraft arriving from malaria-endemic regions. Fraport, the public company that operates Frankfurt Airport, announced Tuesday that the five remaining infected staff members are currently receiving targeted medical care for their infections.

    In a statement shared with the BBC, a Fraport spokesperson confirmed the fatality: “Sadly, we must confirm that one employee has died as a result of the infection.” The operator has since rolled out broad awareness campaigns for all on-site workers, advising anyone who develops malaria symptoms to seek immediate medical attention from a licensed provider. To contain the spread and identify the exact origin and species of the mosquitoes, authorities have deployed dozens of insect traps across airport grounds, with captured specimens set for laboratory analysis.

    The outbreak was first flagged to the public in July, when four cases were initially reported. Germany’s leading public health research and disease control body, the Robert Koch Institute (RKI), later confirmed the four initial cases developed symptoms between July 4 and July 6, reiterating the assessment that infected mosquitoes arrived via aircraft. The institute notes that locally transmitted malaria at a German airport is an extremely rare event: nearly all malaria cases recorded in Germany occur in international travelers who picked up the parasite in high-risk tropical regions.

    In its epidemiological bulletin, the RKI warned that the absence of a recent international travel history among affected workers in this outbreak can lead to critical delays in diagnosis, which in turn raises the risk of severe, life-threatening progression of the disease. The institute also added that the last recorded case of airport-transmitted malaria in Germany occurred in 2023, also at Frankfurt Airport.

    The BBC has reached out to the Frankfurt Public Health Department, which is leading the ongoing investigation into the outbreak, for additional comment on containment efforts and new case tracking.

    According to the World Health Organization (WHO), malaria is a parasitic infection spread exclusively through the bite of specific Anopheles mosquito species, and it is most prevalent in tropical and subtropical climate zones. While the infection is both fully preventable and curable with appropriate medical intervention, it ranges in severity from mild, flu-like symptoms to fatal complications, and cannot spread directly from person to person.

  • Radiation link in flight attendant’s breast cancer, French court finds

    Radiation link in flight attendant’s breast cancer, French court finds

    In a groundbreaking legal decision that could reshape occupational health protections for aviation workers globally, a French court in Bayonne has become the first judicial body in the country to formally link cosmic radiation exposure to a flight attendant’s breast cancer, marking a historic turning point for aviation industry occupational safety.

    The case was brought by 59-year-old Sophie Lainault, a former Air France flight attendant who spent three decades in the air before retiring in 2019. Lainault, who is currently in remission from breast cancer, had petitioned the court to recognize her illness as an occupational disease caused by working conditions inherent to her role. The court’s ruling backed her claim, identifying cosmic radiation as one of three confirmed carcinogenic occupational hazards she faced during her career. The other two documented hazards are prolonged night shifts and chronic exposure to secondhand smoke, a common in-flight condition that persisted on Air France flights until smoking was banned on board in 2000.

    Over her 30-year career from 1989 to 2019, Lainault accumulated a total of 12,600 flight hours, with more than half of those logged on overnight routes. Many of her long-haul high-altitude trips out of Paris operated near the North Pole, a region where cosmic radiation exposure is far more intense than at lower latitudes. Unlike most locations on Earth, the North Pole receives weaker protection from the planet’s magnetic field, which normally deflects the energetic particles that make up cosmic radiation originating from the sun and distant stars.

    The implications of this ruling extend far beyond Lainault’s individual case. For the former flight attendant, the decision unlocks critical benefits: she will now be eligible for early retirement, and all future medical costs related to her cancer will be fully covered by France’s public health system. Legal experts note that the ruling also sets a binding precedent that clears the path for hundreds of other current and former aviation crew members to file similar claims seeking occupational disease recognition for radiation-linked cancers.

    Speaking after the decision, Lainault shared her hope that the ruling would empower other aviation workers to come forward. “My dearest wish is that the decision encourages other women who up until now have not had the courage to take this step,” she said.

    Her lawyer Elisabeth Leroux emphasized the uniqueness of the ruling, explaining that while France had previously recognized links between breast cancer and occupational hazards for workers such as nurses, this is the first time the connection has been formalized for a flight attendant.

    The decision aligns with newly published research from Harvard Medical School in the United States, which underscores the elevated cancer risk faced by aviation crews. A study released by the institution this month analyzed mortality data across more than 500 different professions, finding that flight attendants and pilots have the highest proportion of radiation-related cancer deaths among all occupational groups tracked. Researchers found that roughly 6.9% of all deaths among flight attendants and 6.7% of deaths among pilots are attributable to radiation-related cancers — proportions higher even than nuclear technologists, a profession routinely exposed to non-cosmic radiation, which ranked 12th on the list.

    While it has long been understood that high-altitude air travel exposes people to elevated levels of cosmic radiation, public health experts have long held that the cumulative exposure for occasional leisure travelers is too low to pose a statistically significant cancer risk. For crew members who spend hundreds of hours annually at high altitude, however, cumulative exposure adds up to a measurable long-term health hazard.

    In a statement following the ruling, Air France noted that it had not participated in Lainault’s legal proceedings and had not reviewed the full text of the court’s reasoning. The airline reaffirmed its commitment to employee well-being, saying, “The health and security of our staff is an absolute imperative. Every employee has a medical accompaniment that goes well beyond the regulatory minimum.”

  • Chinese teens are turning to mind-numbing drugs to ‘run away from reality’

    Chinese teens are turning to mind-numbing drugs to ‘run away from reality’

    Against the backdrop of China’s intensely competitive academic culture, a growing number of teenagers are turning to unprescribed recreational use of pharmaceutical drugs to escape crippling study and exam pressure, a hidden public health crisis that has prompted warnings from authorities and experts alike.

    The crisis is illustrated by the story of 14-year-old Xiaomei (a pseudonym to protect her identity), a high-achieving student from a coastal Chinese province who first turned to prescription cough medicine after an older peer suggested it would help her relax. Though the drug required a doctor’s prescription to access legally, she easily purchased it through online platforms. Initially experiencing mild dizziness, Xiaomei quickly grew dependent on the soft numbing effect, which offered a fleeting escape from the anxiety of upcoming high-stakes exams. When consumed in large doses, the medication can trigger severe harmful outcomes, including hallucinations and loss of motor control.

    Over two years, Xiaomei moved between different unprescribed medications shared and recommended to her via anonymous social media chat groups – ranging from epilepsy treatments to neuropathic pain relievers. She sometimes took five pills at a time, occasionally more than 10 to chase the desired calming or intoxicating effect. “When I felt too much pressure from my studies, or I didn’t do well at exams, or even when I quarrelled with my parents, I would take these drugs,” she told the BBC. “I was running away from reality.”

    Xiaomei’s experience is far from unique. The BBC collected dozens of similar accounts from teenagers across Chinese social media chat rooms, where young users collectively pursue what they call a “pharmaceutical high” to cope with uniform academic pressure. In one recorded interaction, a girl shared a slurred, incomprehensible voice note after overdosing on a neuropathic pain drug, saying “I feel my body doesn’t belong to me. I’m so dizzy.” Other users shared tips for accessing unregulated drugs, offered to forge prescriptions using family members’ old documents, and discussed alternate code names for controlled substances to avoid platform detection. For example, one user noted that a Parkinson’s tremor medication, which causes delirium and confusion in excessive doses, remains unregulated and easy to purchase.

    Officially, it is difficult to measure the full scale of this trend due to limited public aggregated data, but the Chinese government has already acknowledged its severity. Two years ago, authorities launched a nationwide crackdown on the cough suppressant many teenagers like Xiaomei first used, reclassifying it as a controlled psychotropic substance that requires a formal prescription. That crackdown made the drug far harder to access online, but by April this year, regulators found teenagers had simply shifted to alternative unprescribed medications. Even after new controls were imposed on the new drug of choice, BBC reporters were still able to purchase it for less than $1.5 per gram via an anonymous online chat room.

    A 2025 research paper from China’s Ministry of Justice Crime Prevention Institute explains why regulatory crackdowns on individual drugs have had limited success: “Non-regulated substances are easy to acquire and even when one drug is controlled by the authorities, young people quickly find alternatives.” As the world’s largest producer of active pharmaceutical ingredients, China has widespread, low-cost access to a huge range of prescription medications, and weak age verification on many platforms lets minors purchase them easily. Xiaomei told the BBC that purchasing a full box of cough suppressant only took a few clicks – she simply entered her national ID number (which clearly displays her underage status) and received the delivery with no additional checks, paying less than $1 for 50 tablets.

    While official 2025 data shows a 41% drop in newly identified drug users under 35, the China National Narcotics Control Commission has issued explicit warnings that non-medical prescription drug misuse is growing rapidly, particularly among minors. Experts point to the uniquely intense pressure facing Chinese teenagers as the root cause of the trend.

    Xiaomei, who attended an elite academic class with a strict elimination system – students who drop in rankings are removed from the advanced program – explains the stakes: “It is just so hard to pass exams and to stay in elite classes. When you fail, you feel like a failure, believing you have no chance in life.”

    Renowned Chinese sociologist Xiang Biao, director of the Max Planck Institute for Social Anthropology, notes that decades of the now-ended one-child policy left many families with a single child who carries all of their household’s future expectations, compounding that pressure. “What makes Chinese teens different is their isolating environment,” Xiang explains. “They spend at least nine or 10 hours in school. They have very few chances to develop social relationships, very few opportunities to witness what life is really like.” Xiang also links rising prescription drug misuse to a documented increase in teen self-harm, a trend the BBC observed in chat rooms where users encouraged one another to self-injure “to feel something”.

    For Xiaomei, the misuse of drugs took a severe physical toll. As the critical high school entrance exam approached, she switched to a new epilepsy and pain management drug to numb her anxiety, and quickly experienced rapid memory deterioration, living in a constant mental fog. After being advised to switch to another pain reliever, she eventually overdosed on 50 tablets, becoming severely ill and forced to confess to her parents. Unlike many families, Xiaomei’s parents responded with empathy rather than anger: “They mostly expressed how heartbreaking it was for them to see me like that. They didn’t scold or criticise me. Their approach was gentle.” This shift in support, she says, changed everything.

    Xiang notes that this lack of emotional validation is a common gap for Chinese teens: “Many children receive lots of attention but the type of attention they want is to be asked how they feel. Do they feel lonely or stressed? Often in China parents brush that away and say you just have to be stronger.” Experts argue that rather than focusing solely on cracking down on illegal online drug sales – a strategy they compare to playing whack-a-mole – policymakers should address the underlying teen mental health crisis driving the trend. Recent data underscores the scale of that crisis: a 2023 China Mental Health Blue Book study found that nearly 95 million people in China live with depression, and over 30% of that group are under 18.

    The Chinese government has acknowledged the need for expanded mental health support for teenagers, and has announced plans to roll out counselling rooms in all schools, add psychiatric services to at least one hospital per county, and train more mental health professionals, with a goal of building a national psychological support and crisis intervention system by 2030. To date, 92% of primary schools and 95% of junior secondary schools have employed on-campus counsellors, and major cities including Beijing have integrated mental health education into standard school curricula. However, the system still faces a critical shortage of specialized child and adolescent psychiatrists: a 2020 study published in *The Lancet* found only 500 qualified child psychiatrists across the entire country, most concentrated in major urban centers.

    Wider social and economic shifts have also amplified teen and parental anxiety. The China that Xiaomei’s parents grew up in followed a clear social contract: hard work and strong grades guaranteed stable success. Today, even high grades and a university degree do not guarantee a secure future, particularly after the COVID-19 pandemic left China’s economy struggling to recover, with youth unemployment reaching 20% in recent estimates. “People have become more pessimistic in general,” Xiang says. “Parents feel confused and anxious because they see a problem in their children, but they don’t see an alternative. If my child has a problem, it’s the end of the world. I think we should pay more attention to parents as well as children.”

    For Xiaomei, her parents’ new willingness to listen helped her recover, and she ultimately performed well on the entrance exam that had caused her so much anxiety. “I am lucky to have their support,” she says. But not all teens have access to that kind of support, which is why 22-year-old Lu Jingchan, a former prescription drug user who overcame addiction after four years and four overdoses, now advocates against teen misuse on social media. “The drugs drove me to the brink of madness. You risk sinking into an abyss of addiction, destroying your health,” he says. His message to teens struggling with the pressure he once faced is direct: “I hope you can face life head-on, without needing medicines to numb yourselves. If you are overdosing, I want to give you the courage to stop. I believe your lives will improve. I believe you will all find happiness.”

  • Two unvaccinated people die of measles in Pennsylvania

    Two unvaccinated people die of measles in Pennsylvania

    The United States is facing its most severe measles outbreak in three and a half decades, with two unvaccinated individuals in Pennsylvania becoming the latest fatalities of the highly contagious viral disease, state health officials have confirmed.

    As of the eighth month of 2026, the Centers for Disease Control and Prevention has recorded 2,777 confirmed measles cases across the country, a figure that already surpasses 2025’s total of 2,289 cases — the previous high for decades. This growing public health crisis is rooted in years of rising vaccine hesitancy that has pushed childhood immunization rates below the threshold needed for effective herd protection.

    In Lancaster County, the location of the two recent deaths, just 85% of kindergarten-age children have received the measles, mumps, and rubella (MMR) vaccine. That rate falls far short of the 95% herd immunity benchmark required to slow transmission and shield immunocompromised community members who cannot receive the vaccine themselves. This is not the first deadly measles incident in recent years: in 2025, two unvaccinated children in Texas died during an outbreak that infected more than 1,000 people, most of them under 18. So far in 2026, Pennsylvania alone has logged 393 confirmed cases.

    Pennsylvania Secretary of Health Debra Bogen extended condolences to the families of the deceased in an official statement, noting that decades of near-elimination have left many Americans unaware of how dangerous the virus can be. “Because measles was largely eliminated in the Commonwealth for more than three decades, people are not familiar with this disease and don’t fully understand the potential severity of the illness,” Bogen said. She reaffirmed that the standard two-dose MMR vaccine regimen, recommended for all children between 1 and 6 years old, remains the most effective defense against measles, with clinical data showing it is 97% effective at preventing infection. State health officials have not released any additional details about the identities of the two people who died to protect family privacy.

    The accelerating outbreak has unfolded alongside controversial shifts in federal vaccine policy led by the Trump administration. Earlier this month, former President Donald Trump signed an executive order calling for reduced childhood vaccination volumes and splitting the combined MMR vaccine into three separate individual doses. Public health experts across the country have warned that the order will spread unnecessary confusion about a vaccine that has been proven safe and effective for more than half a century, and will create additional costs for healthcare providers and families.

    The order is the latest policy change from Health Secretary Robert F. Kennedy Jr., a prominent vaccine skeptic who has led a widespread overhaul of national vaccine policies and childhood immunization schedules over the past year. Most of Kennedy’s proposed changes were already blocked by a federal judge earlier in 2026. Kennedy has sent inconsistent public messages about the MMR vaccine: he has occasionally issued weak endorsements of the shot while repeatedly sharing unsubstantiated, debunked claims about its safety.

    By the end of 2026, an international public health panel will review whether the United States will lose its measles elimination status, a designation it has held for nearly two decades. Canada lost this status in 2025 amid its own rising outbreak driven by low vaccination rates, and current trends put the United States on track to follow suit.

  • Congo’s Ebola outbreak records one of its highest weekly death tolls yet

    Congo’s Ebola outbreak records one of its highest weekly death tolls yet

    BUNIA, Democratic Republic of Congo – Fresh government data released Monday has revealed a catastrophic milestone in the ongoing Ebola crisis gripping eastern Congo, with more than 300 fatalities recorded in the past seven days alone — one of the sharpest weekly death tolls since the outbreak began. As frontline health teams fight against overwhelming odds to contain the virus, the epidemic is spreading at a rate never before seen in global Ebola history.

    According to figures from Congo’s Ministry of Health, as of Saturday, the outbreak has been linked to 5,514 confirmed and probable cases, with a total of 2,642 deaths nationwide. The 317 new fatalities reported over the previous week mark a dangerous acceleration in the virus’s spread. Congolese public health experts warn the true scale of the crisis is far worse than official numbers indicate, noting the virus was circulating undetected for weeks before the outbreak was formally confirmed, and the actual case count could be three times higher than currently documented.

    This outbreak, caused by the rare Bundibugyo Ebola variant, is now the fastest-growing on record. A large share of deaths are occurring outside of formal treatment centers, and at this stage of the outbreak, the death toll is already seven times higher than that of the 2014–2016 West Africa Ebola outbreak at the same point, despite that outbreak eventually becoming the deadliest in history with more than 11,000 total fatalities.

    Ituri province remains the epicenter of the crisis, and data shows that most new infections are still occurring among people who were not part of monitored contact tracing networks, making early intervention and isolation nearly impossible. The overall national case fatality rate currently stands at 47.9%, but hard-to-access regions like neighboring North Kivu province face far deadlier outcomes, with a fatality rate reaching 68.6% according to government data.

    One of the biggest barriers to containing the spread has been the absence of formally approved vaccines or targeted treatments for the rare Bundibugyo variant driving this outbreak. In a small glimmer of progress, Congo received more than 16,000 doses of the Ervebo vaccine on Friday — a jab that has proven highly effective against the more common Zaire Ebola variant in past outbreaks. The World Health Organization has announced that the doses will first be offered to frontline medical workers, and will also be used to support clinical trials for a Bundibugyo-specific vaccine.

    While early laboratory and animal studies suggest Ervebo may offer some cross-protection against the Bundibugyo variant, public health officials have not yet confirmed its effectiveness against this specific strain. Authorities have not yet announced a timeline for rolling out the vaccine doses to at-risk frontline workers, but local residents in Ituri expressed cautious optimism that the arrival of vaccines will help turn the tide of the outbreak.

    “I am very pleased that these vaccines have finally arrived,” said Héritier Ramazani, a local Ituri resident. “We are fed up with recording new cases of Ebola every day.”

    The response effort is already hindered by a collection of overlapping challenges that make containing the virus extraordinarily difficult. The outbreak is centered in a region plagued by ongoing rebel violence that puts response teams at constant risk, alongside massive, unregulated population movements that help the virus spread across provincial and national borders. Medical teams also face unpaid salaries that have led to repeated work stoppages, deep-seated community mistrust built from decades of conflict, poor road infrastructure that slows access to remote communities, and widespread misinformation that claims Ebola does not exist at all.

    Epidemiologists tracing the outbreak’s origins believe the virus began spreading in the mining town of Mongbwalu as early as February, roughly three months before Congolese authorities officially declared the outbreak on May 15. The months of undetected transmission allowed the virus to take hold across multiple communities before response efforts could even begin.

  • China probes use of formaldehyde to keep cabbages fresh

    China probes use of formaldehyde to keep cabbages fresh

    As the world’s leading cabbage producer, accounting for nearly half of the global annual output that exceeds 30 million metric tons, China is now facing a fresh food safety scare that has sparked nationwide attention. Hebei Province, a key growing and distribution hub in the country’s northeast, has confirmed that authorities have launched a full investigation following the emergence of footage showing cabbage handlers dipping heads of the vegetable in a preserving solution before loading them onto transport trucks.

    The controversial footage was first brought to public attention by an independent environmental blogger last week. In China, the use of formaldehyde — a colorless, carcinogenic chemical — for any food preservation purpose is banned under strict national food safety regulations. Most of China’s cabbage output is distributed domestically, with a large share also exported to neighboring Asian markets and Russia, with South Korea and Vietnam counting among the top international buyers.

    State media reports confirm that local police have already initiated legal proceedings against the individuals identified as being involved in the practice. In response to growing public concern, national and local regulators have moved quickly to head off widespread consumer panic and rebuild public trust in the country’s fresh vegetable supply. Authorities are rolling out widespread random spot checks of cabbage stocks at wholesale and retail markets across every region of the country.

    Investigators are also working to determine how widespread the illegal practice of formaldehyde dipping is across the cabbage industry, and have implemented tracing protocols to isolate and remove any affected produce from the supply chain. In an official public statement released Saturday, administrators from Kangbao County, the region at the center of the initial reports, reaffirmed their commitment to upholding food safety standards: “Any illegal or non-compliant practices discovered will be dealt with strictly in accordance with the law to ensure the safety of the vegetable supply.”

    Beijing’s Xinfadi Market, the largest wholesale fresh produce hub serving the Chinese capital, released its own statement confirming that it had completed a full audit of its cabbage supply chains, and that no contaminated produce had entered the market’s distribution network.

    The incident has dominated domestic Chinese media coverage and sparked intense public discussion. In an official editorial, People’s Daily, the official newspaper of the Chinese Communist Party, issued a sharp rebuke of the actors involved: “The wholesalers focused solely on their immediate economic interests while completely disregarding the lives and health of consumers. [They] crossed a legal red line and breached the moral bottom line.”

    According to the American Cancer Society, while prolonged exposure to high concentrations of formaldehyde in occupational settings has been definitively linked to multiple forms of human cancer, the long-term health impacts of low-level exposure through food consumption remain understudied and not clearly understood.

  • Congo receives more than 16,000 doses of Ebola vaccine as it grapples with unprecedented outbreak

    Congo receives more than 16,000 doses of Ebola vaccine as it grapples with unprecedented outbreak

    BUNIA, Democratic Republic of the Congo – As the Central African nation fights what has become the fastest-spreading Ebola outbreak in recorded history, its first shipment of 16,250 doses of the Ervebo vaccine has arrived on the ground, the country’s health minister confirmed.

    The vaccine shipment touched down at Kinshasa’s N’djili International Airport on Friday evening. This delivery marks the first installment of the 70,000 total doses promised to Congo by the World Health Organization and its global health partners, an aid package first announced publicly this past Thursday. Additional shipments of more vaccine doses are scheduled to arrive in the country early next week, according to official updates.

    The unfolding public health crisis is being driven by the Bundibugyo Ebola virus strain, a rare variant that currently has no specifically approved treatment or licensed vaccine designed exclusively to target it. The virus presents a unique challenge to containment: its early symptoms overlap heavily with common regional illnesses like malaria, allowing infections to go undetected while the virus spreads easily through communities.

    While Ervebo is formally approved only for another common Ebola strain, it has a proven track record of successfully stopping transmission in past outbreaks. WHO public health experts have indicated the vaccine may still offer meaningful cross-protection against the Bundibugyo variant, making it a critical stopgap tool while more targeted medical countermeasures are developed.

    As of Friday’s official count, the outbreak has already claimed 2,516 lives among 5,290 confirmed confirmed cases. The rate of spread is unprecedented, and public health officials warn the outbreak is on course to overtake the 2014-2016 West African Ebola epidemic, the deadliest on record which killed more than 11,000 people across five countries. Data analysis from the Africa Centers for Disease Control and Prevention shows transmission has not yet reached its peak, with projections indicating the known infection rate could triple in coming weeks if containment efforts cannot slow spread.

    Complicating all response efforts are a series of overlapping humanitarian and security crises that have blocked access to affected communities. Much of the outbreak’s epicenter is controlled by rebel groups engaged in active armed conflict with the Congolese government, making it dangerous for response teams to operate. Medical workers and facilities have repeatedly been targeted in attacks, while large populations of displaced people and mobile migrant laborers have helped the virus cross regional borders. The lack of basic healthcare infrastructure in affected regions has further undermined efforts to test, trace, and isolate cases.

  • Ebola vaccine trial to start in DR Congo as warning issued over speed of infections

    Ebola vaccine trial to start in DR Congo as warning issued over speed of infections

    The Democratic Republic of the Congo (DRC) has launched a new phase of its battle against a historic Ebola outbreak, rolling out an existing vaccine for clinical trials to test its effectiveness against the rare Bundibugyo strain that is currently driving the spread of the virus. As the World Health Organization (WHO) warns that infections are growing at an exponential rate across large swathes of northern and eastern DRC — an area larger than the entire country of France — the death toll from the three-month outbreak has already climbed to nearly 2,500, with half of these fatalities recorded in just the last 20 days.

    This outbreak is already the deadliest ever recorded in DRC and the second-worst Ebola outbreak in global history, outstripped only by the devastating 2014–2016 West Africa epidemic that killed more than 11,000 people. Experts now believe the Bundibugyo strain has been circulating in the country since as early as February, but initial cases were misdiagnosed as more common regional illnesses including typhoid and malaria, creating a critical delay in response efforts.

    Multiple barriers have continued to slow containment work. Years of armed conflict in eastern DRC has left large areas of territory inaccessible to official public health teams, while deep-rooted local suspicion of government health authorities and traditional burial practices that involve close contact with deceased bodies have further accelerated transmission. A new analysis from international children’s charity Save the Children estimates that at least 180 Congolese children have been orphaned, losing both parents or primary caregivers to the virus since the outbreak began.

    In a new effort to turn the tide of the crisis, the existing Ervebo vaccine — which is already proven to protect against the more common Zaire strain of Ebola — will be deployed in a large-scale clinical trial. Under the plan agreed with global health bodies, 20,000 doses of Ervebo will be used to test how well it works against the Bundibugyo strain, for which no effective vaccines or treatments have yet been validated. An additional 50,000 doses will be prioritized for frontline health workers, who have faced extraordinarily high risk of infection during the response. Both the WHO and the Africa Centres for Disease Control and Prevention have welcomed the vaccine allocation, framing it as a critical reinforcement for the under-resourced response to the rapidly spreading outbreak. Strict new safety protocols have also been put in place for burials to cut the risk of transmission from infected remains.

    The ongoing conflict has added unprecedented complexity to the crisis. The M23 rebel alliance, which seized control of major eastern cities including Goma and Bukavu in early 2025 and holds large portions of North Kivu province, has launched its own parallel Ebola response in the territories it controls. After confirming two positive Ebola cases in a village under its control, M23 authorities recently announced a 30-day suspension of shared taxis and passenger boat travel between rebel-held and government-held areas of North Kivu, effective this Saturday. All other cross-area transport will remain operational but subject to strict public health screening. The rebel group had declared its territories Ebola-free in late June, and the new restrictions highlight how armed divisions have fragmented the response to a unified public health threat.

    Ebola is an extremely virulent viral disease, and the Bundibugyo strain is one of the rarest variants, with only two documented prior outbreaks recorded globally. Initial symptoms of infection mirror those of common regional illnesses, including sudden fever, headache, and fatigue, and can develop anywhere from two to 21 days after exposure. As the infection progresses, patients often develop severe vomiting and diarrhea that can lead to fatal organ failure. The virus spreads through direct contact with infected bodily fluids such as blood or vomit, making infection control particularly challenging in low-resource, conflict-affected settings.